Search

everythinglearnresearchcommunity

for

Search:↓

TWIST-1 gene's role in hair loss and potential as a treatment target. Inhibiting TWIST-1 may prolong hair growth and reduce hair follicle sensitivity to DHT.

The conversation is about the impressive hair density and hairline of a person, with users attributing it to good genetics and joking about the lack of hair loss despite stress. Specific hair loss treatments like Minoxidil, Finasteride, or RU58841 are not discussed.

Chime Biologics and Hope Medicine are speeding up the launch of a first-in-class antibody drug, HMI-115, for endometriosis and androgenic alopecia. The treatment involves a series of subcutaneous injections, has shown promising results in phase 1, and continues to promote hair regrowth even after the treatment is stopped.

Slow_Class_4465's progress using finasteride and minoxidil to address hair loss, which has resulted in drastic improvement. Other users have shared their experiences with the treatments, including possible side effects.

A user's 6 month progress using finasteride and minoxidil as treatments for hair loss, with the replies discussing side effects and general consensus about usage of the two medications.

Microneedling may enhance hair regrowth by transferring stem cells to dormant follicles, improving the effects of minoxidil. Users discuss using microneedling with needle lengths around 1.5mm to stimulate hair growth.

The conversation is about someone seeking a finasteride prescription for hair loss, who later finds finasteride at a local pharmacy. Minoxidil and finasteride are mentioned as treatments.

Hair loss treatments discussed include Minoxidil, Finasteride, and RU58841. HMI-115, a monoclonal antibody drug, is in phase 1 and 2 trials for different conditions, but its availability on the gray market is unlikely due to high production costs.

The conversation humorously discusses hair loss and its treatments, specifically mentioning Minoxidil, finasteride, and RU58841. It highlights a transformation from hairline recession to significant hair regrowth.

Breezula's phase 3 results are expected soon, with discussions on the effectiveness of androgen receptor antagonists like spironolactone and the potential of GT20029. Users express skepticism about new treatments and discuss the complexities of male pattern baldness, often relying on finasteride despite its side effects.

The conversation is about someone experiencing slow but steady hair regrowth using topical Minoxidil and 1mg Finasteride daily since mid-December. Another person commented positively on the progress.

Pelage Pharmaceuticals' PP405 aims to treat hair loss by reactivating dormant hair follicle stem cells, showing promising results in early trials. The company plans to present their findings at the American Academy of Dermatology Annual Meeting in 2026.

A young person struggling with hair loss switched from finasteride to 0.5mg dutasteride and Oral Minoxidil 2.5mg, hoping for improvement before graduation. They are considering a hair transplant and exploring other treatments like stemoxydine and hair fibers, while dealing with the emotional impact of early balding.

PP405 may damage hair follicles if used long-term, suggesting cycling might be necessary. Combining it with finasteride could help maintain hair growth.

Finasteride and dutasteride can prevent hair loss if used early, but they may cause side effects. Many men shave their heads because they are unaware of these treatments or avoid them due to side effects or cost.

A user is interested in Absci's AI-driven antibody platform, ABS-201, for treating androgenetic alopecia, which shows promising preclinical results and potential for hair regrowth and pigmentation restoration. However, concerns are raised about the drug's development timeline and its advantages compared to existing treatments.

Liquid minoxidil makes hair sticky and stiff; users suggest oral minoxidil or minoxidil foam as alternatives. Applying minoxidil four hours before showering can help with absorption.

Promising hair loss treatments in clinical trials include Pyrilutamide, GT20029, CB-03-01, and PP405, with potential market releases between 2027 and 2029. Hair cloning remains experimental and expensive, while existing treatments like finasteride, minoxidil, and microneedling continue to be used.

The conversation discusses the impact of hair loss treatments like dutasteride and finasteride, with some users expressing skepticism about media claims linking these drugs to severe side effects like suicidal ideation. Many participants criticize the media, particularly British tabloids, for fearmongering and emphasize the psychological impact of hair loss itself.

Many people become hyper-aware of hair loss in themselves and others, often leading to feelings of jealousy or self-consciousness. Treatments like finasteride, minoxidil, and dutasteride are commonly discussed as solutions to combat hair loss.

Dutasteride and finasteride are discussed for hair loss treatment, with users sharing experiences and debating their effectiveness and side effects. Celebrities are noted as common users, and there is debate over which treatment is superior.

DLQ01, a prostaglandin F2α analog, shows promise for hair growth by directly stimulating PGE2/PGF receptors without needing conversion, and can be combined with minoxidil and retinoids like tretinoin for enhanced effectiveness. Minoxidil's efficacy may be reduced by COX-1 inhibitors, but using prostaglandin analogs like Latanoprost or Bimatoprost can help maintain its effectiveness.

A user is developing a tool to track hair density, aiming to help those using treatments like minoxidil. They seek feedback on the tool's usefulness and are considering a low-cost model to cover expenses.

RU58841 is discussed as a potential hair loss treatment, with comparisons to finasteride. There is interest in leaked trial data, but no official clinical validation or approval for RU58841.

A user discusses a topical prescription for hair regrowth containing Minoxidil, Finasteride, and Latanoprost, noting Latanoprost's side effect of promoting eyelash and eyebrow growth. Others share experiences and information about Latanoprost, highlighting its origins as a glaucoma drug and potential side effects.

A 20-year-old experiencing hair loss since age 16 is using finasteride and minoxidil and is considering future hair transplants. Discussions include the potential for multiple transplants, the use of body hair for coverage, and the importance of treatments like dutasteride and scalp micropigmentation for maintaining hair density.

Microneedle pens for hair loss are harder to find on Amazon due to FDA regulations on needle length. Users suggest buying from AliExpress or Temu instead.

A 22-year-old is struggling with hair loss despite using treatments like minoxidil, finasteride, dutasteride, castor oil, rosemary, argan oil, and microneedling. Stress and poor sleep are worsening the condition, and they seek advice as current treatments have been ineffective.

The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.

The user reports hair regrowth after three months using a daily oral capsule with Minoxidil, Finasteride, and Biotin, derma stamping twice a week, and alternating Nizoral and Mane Root Activator Shampoo, with no side effects except increased nasal hair growth. They observed significant progress on the crown and thickening of the hairline.